[ SOURCE: Reuters] As of June 2, 2025, the JPML reports there are 1,882 cases pending in the MDL -3094 IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation
Pipeline and Technology Innovation Analysis GLP-1 Weight Loss Drug Market Pipeline: Triple Agonists, Oral Formulations, and Amylin Combinations Define the 20262035 Innovation Frontier Key GLP-1 Pipeline Molecules, Mechanisms, Development Stage, and Peak Sales Projections Triple agonist therapies targeting GLP-1, GIP, and glucagon receptors simultaneously represent the most significant efficacy advance in obesity pharmacotherapy since semaglutide
Kisspeptin activates GnRH neurons, which release gonadotropin-releasing hormone, driving luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion
Studies in animal models suggest that diet-induced obesity alters intestinal microbial composition and reduces endogenous GLP-1 levels, reinforcing the interdependence of these systems
To try to prevent that loss, researchers combined bimagrumab with semaglutide in a clinical trial involving more than 500 people
